Aurinia Pharmaceuticals Inc.

Aurinia is incorporated in Alberta, Canada, but its commercial revenue is heavily tied to the United States, where LUPKYNIS is sold through specialty channels. Ex-U.S. business is concentrated in the Otsuka Territories, including Japan, the European Union, the U.K., Switzerland and several smaller markets, where Otsuka commercializes voclosporin. The company also relies on a supply chain that imports certain products into the U.S. primarily from Switzerland, which creates cross-border manufacturing and trade exposure. Geography matters because U.S. policy, tariffs, and import restrictions could affect both Aurinia’s direct supply chain and Otsuka’s downstream commercialization economics.

Aurinia is highly exposed to the commercial performance of LUPKYNIS, so slower-than-expected uptake, competitive pressure, or reimbursement challenges could materially affect results. The company also depends on sole-source contract manufacturers and third-party logistics and clinical partners, which creates supply interruption and execution risk. Regulatory and patent protection matter because generic or ANDA challenges could erode exclusivity, while the company is already litigating to defend LUPKYNIS patents. In addition, U.S. trade policy and retaliatory actions in Otsuka Territories could disrupt cross-border supply and commercialization, and the broader autoimmune drug market remains competitive with injectable therapies and investigational BAFF/APRIL competitors.